Eli Lilly raised its full-year revenue forecast to $91-$92 billion driven by surging GLP-1 weight-loss drug sales, beating Q3 earnings expectations despite trimming profit guidance due to acquisition
A US judge denied Novo Nordisk's motion to block Eli Lilly's advertising for weight-loss drugs, finding claims of irreparable harm inadequate. The decision affects competition in the obesity drug mark
The US FDA approved Eli Lilly's once-weekly basal insulin Onswik for type 2 diabetes, potentially reducing annual injections by over 300 compared to daily alternatives. Approval followed late-stage tr
Eli Lilly launched its oral weight-loss drug Foundayo (orforglipron) in the UK, marking the first European availability and offering a lower price point than injectable alternatives while pending EU r
Eli Lilly sued six companies for illegally selling unapproved black-market versions of its experimental obesity drug retatrutide, currently in Phase 3 trials. Highlighting safety risks, the firm urged
Eli Lilly announced an expanded access program for its experimental obesity drug retatrutide prior to FDA approval for specific severe cases. The company plans to file for approval in Q1 next year fol
Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion to access its lead psychedelic candidate BPL-003 for treatment-resistant depression. The deal marks Lilly's latest move into neuroscience
AtaiBeckley shares surged 50% premarket following reports that Eli Lilly is negotiating to acquire the psychedelic drug developer in a deal potentially exceeding $2 billion. The potential acquisition
Eli Lilly agreed to acquire biotech firm AtaiBeckley for $2.8 billion upfront plus potential milestones, expanding its neuroscience portfolio into the psychedelics market.
German Health Minister Nina Warken confirmed drugmakers will not be exempt from new cost-cutting legislation aimed at capping health insurance expenses. Consequently, major firms like Eli Lilly and Pf
Eli Lilly shares rose 4% following compelling Phase III data for obesity drug retatrutide, showing 19% weight loss at a lower dose. Analysts view this as strengthening Lilly's leadership against rival
S&P 500 and Nasdaq futures rose as chip stocks rebounded, while crude oil prices surged over 4% amid Middle East tensions. Eli Lilly shares gained following positive clinical trial results for its obe
Eli Lilly plans to spend up to $3.8 billion to acquire three vaccine makers, expanding its immunology portfolio with candidates targeting shingles, bacteria, and viruses.
Eli Lilly rises on obesity shot trial data, Borr Drilling falls on rig delays; US indices slip amid Middle East tensions and mixed tech earnings.
The U.S. Supreme Court declined to hear Eli Lilly's appeal against a $183 million Medicaid fraud judgment upheld under the False Claims Act. The ruling confirms private whistleblowers can continue sui
Novo Nordisk reports strong early demand for its new oral weight-loss pill despite intensifying competition from Eli Lilly. Investors await Q1 earnings to determine if volume growth can offset rising
Eli Lilly and Merck rose on drug sales forecasts, while Ford cited rising commodity costs; broader US indices climbed following strong tech earnings reports.
Eli Lilly raised its full-year profit and revenue forecasts driven by surging GLP-1 drug demand, offsetting U.S. pricing pressures. First-quarter adjusted profit per share exceeded Wall Street estimat
Eli Lilly investors await detailed sales insights for the newly launched weight-loss drug Foundayo, as early data falls outside current quarterly reports. Market focus remains on global demand strengt
Eli Lilly will acquire Centessa Pharmaceuticals for $6.3 billion, with an additional $1.5 billion contingent on FDA approval of its narcolepsy drug candidates. Analysts believe the acquired drug has b
Dow announced 4,500 job cuts linked to AI automation amid a chemical industry downturn, while the weekly watch also highlighted catalysis startup funding and Eli Lilly's biotech deals.
ChemBrief